Showing 1 - 7 results of 7 for search 'Jan Erik Berdal', query time: 0.03s Refine Results
  1. 1
    Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital.

    Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital. by Jan-Erik Berdal, Rolf Haagensen, Trond Ranheim, Jørgen V Bjørnholt

    Published 2014-01-01
    Get full text
    Article
  2. 2
    SARS‐CoV‐2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID‐19

    SARS‐CoV‐2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID‐19 by Peder L. Myhre, Christian Prebensen, Christine Monceyron Jonassen, Jan Erik Berdal, Torbjørn Omland

    Published 2021-05-01
    Get full text
    Article
  3. 3
    Author Correction: Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19

    Author Correction: Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19 by Christian Prebensen, Yohan Lefol, Peder L. Myhre, Torben Lüders, Christine Jonassen, Anita Blomfeldt, Torbjørn Omland, Hilde Nilsen, Jan‑Erik Berdal

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19

    Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19 by Christian Prebensen, Yohan Lefol, Peder L. Myhre, Torben Lüders, Christine Jonassen, Anita Blomfeldt, Torbjørn Omland, Hilde Nilsen, Jan-Erik Berdal

    Published 2023-06-01
    Get full text
    Article
  5. 5
    Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

    Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coron... by Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard

    Published 2020-06-01
    Get full text
    Article
  6. 6
    A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

    A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics by Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Corina Silvia Rueegg, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard

    Published 2020-10-01
    Get full text
    Article
  7. 7
    Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway.

    Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway. by Kristin G-I Mohn, Rebecca Jane Cox, Gro Tunheim, Jan Erik Berdal, Anna Germundsson Hauge, Åsne Jul-Larsen, Norwegian Pandemic Group, Bjoern Peters, Fredrik Oftung, Christine Monceyron Jonassen, Siri Mjaaland

    Published 2015-01-01
    Get full text
    Article

Search Tools: